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Introduction: Patients with chronic airway disease may present features of both asthma and 
COPD, commonly referred to as asthma–COPD overlap syndrome (ACOS). Recommenda-
tions on their diagnosis are diffuse and inconsistent. This survey aimed to identify consensus 
on criteria for diagnosing ACOS.
Methods: A Belgian expert panel developed a survey on ACOS diagnosis, which was completed 
by 87 pulmonologists. Answers chosen by 70% of survey respondents were considered as use-
ful criteria for ACOS diagnosis. The two most frequently selected answers were considered as 
major criteria, others as minor criteria. The expert panel proposed a minimal requirement of two 
major criteria and one minor criterion for ACOS diagnosis. Respondents were also asked which 
criteria are important for considering inhaled corticosteroids prescription in a COPD patient.
Results: To diagnose ACOS in COPD patients, major criteria were “high degree of variability 
in airway obstruction over time (change in forced expiratory volume in 1 second 400 mL)” and 
“high degree of response to bronchodilators (200 mL and 12% predicted above baseline)”. 
Minor criteria were “personal/family history of atopy and/or IgE sensitivity to 1 airborne 
allergen”, “elevated blood/sputum eosinophil levels and/or increased fractional exhaled nitric 
oxide”, “diagnosis of asthma 40 years of age”; “symptom variability”, and “age (in favor of 
asthma)”. To diagnose ACOS in asthma patients, major criteria were “persistence of airflow 
obstruction over time (forced expiratory volume in 1 second/forced vital capacity ratio 0.7)” 
and “exposure to noxious particles/gases, with 10 pack-years for (ex-)smokers”; minor 
criteria were “lack of response on acute bronchodilator test”; “reduced diffusion capacity”; 
“limited variability in airway obstruction”; “age 40 years”; “emphysema on chest computed 
tomography scan”.
Conclusion: Specific criteria were identified that may guide physicians to a more uniform 
diagnostic approach for ACOS in COPD or asthma patients. These criteria are largely similar 
to those used to prescribe inhaled corticosteroids in COPD.
Keywords: ACOS, airway obstruction, asthma, COPD, diagnosis, inhaled corticosteroids
Introduction
COPD and asthma are the two main chronic inflammatory diseases of the airways, 
and both are characterized by airflow limitation. While asthma is a clinically defined 
syndrome that typically develops early in life in association with allergy, COPD is 
generally not diagnosed below the age of 40 years and is caused by chronic exposure to 
noxious particles or gases, mainly tobacco smoke. COPD is characterized by a persistent 
airflow obstruction, defined by a ratio of forced expiratory volume in 1 second over 
forced vital capacity (FEV
1
/FVC ratio) below 0.7, or below the lower normal limit.1
In some patients, features of both diseases may coexist. They are commonly 
referred to as having asthma–COPD overlap syndrome (ACOS), as proposed by the 
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Global Initiative for Asthma/Global Initiative for Chronic 
Obstructive Lung Disease (GINA/GOLD) statement and 
other working groups.2,3 The reported frequency of ACOS 
in populations of COPD patients varies widely, depending 
on the methodology of the study.4 ACOS prevalence rates 
range from 15% to 60%, reflecting variations according to 
the age group, the population sampled, and the definitions of 
asthma and COPD.5 Based on observations of clinical stud-
ies, which tend to be more reliable, between 5% and 21% of 
COPD patients were diagnosed as having ACOS4 when using 
the Spanish criteria for diagnosis.2 The prevalence of ACOS 
in asthma patients with a smoking history was estimated to 
be 27% in a cross-sectional study in Finland.6 The disease 
presentation and response to therapy in ACOS patients might 
differ from those with COPD or asthma alone. Scientific data 
characterizing ACOS patients are scarce since these patients 
have generally been carefully excluded from clinical studies, 
which only include patients with an unequivocal diagnosis 
of asthma or COPD.7–9
ACOS patients are usually older than 40 years, but 
respiratory symptoms might have started in childhood or 
early adulthood. In most cases, there is a previous diagnosis 
of asthma by a health care professional, family history of 
asthma or allergies, or exposure to noxious gases or par-
ticulate matter.1
In ACOS patients, airflow limitation measured by spirom-
etry is not fully reversible to β
2
-mimetics, which is a major 
COPD feature, and chest X-ray findings are not specific. 
However, it is now well established that at least 39% of 
COPD patients actually display significant reversibility in 
response to bronchodilators, although the clinical meaning 
of this trait remains unclear.10
Airway inflammation measured in sputum samples or 
bronchoalveolar lavage is characterized by the presence of 
eosinophils and/or neutrophils. Interestingly, a cohort study 
conducted in Belgium recently showed that 37% of stable 
smoking COPD patients display sputum eosinophilia 3%,11 
further illustrating difficulties in categorizing such patients 
presenting with combined asthma and COPD features.
Repeated exacerbations decrease the quality of life and 
increase mortality and health-related costs in asthma and 
COPD patients. Medications such as inhaled corticoster-
oids (ICS), long-acting β-agonists (LABA), long-acting 
muscarinic antagonists (LAMA), or combinations of these 
medications were shown to have a favorable impact on 
both asthma and COPD exacerbations in placebo-controlled 
studies.12–19 A recent study demonstrated that LABA/LAMA 
associations might prevent exacerbations to a similar extent 
as compared to some LABA/ICS combinations.20 As COPD 
patients might mostly benefit from bronchodilator therapies 
(LAMA, LABA, or their combination), there is a challenge 
for the clinician to recognize an asthma component that will 
require ICS prescription.2
Given the lack of scientific evidence regarding the diag-
nosis and treatment of ACOS patients and the complexity of 
this phenotype,21 there is an important need for recommen-
dations on its diagnosis, for both general practitioners and 
specialist pulmonologists. In addition, as recently proposed 
by Sin et al9 and others, a general and workable consensus 
on inclusion and exclusion criteria is urgently needed to 
conduct future studies on the diagnosis, management, and 
outcome of ACOS patients.
A national “ACOS working group” was set up in Belgium 
to reach consensus on criteria considered to be crucial for 
diagnosing ACOS. A diagnosis of asthma or COPD is often 
proposed after a first visit, while ACOS is rarely diagnosed 
at this time because longitudinal follow-up is needed. There-
fore, criteria were assessed that could be considered for 
diagnosing ACOS either in an asthma patient or in a COPD 
patient. Additionally, because ACOS patients often require 
ICS therapy, criteria considered by specialists for initiating 
ICS therapy in COPD patients were also investigated.
Methodology
An online survey was set up by a panel of Belgian experts 
in the field of asthma and COPD. The results of this survey 
were analyzed and discussed by the expert panel.
Inclusion/exclusion criteria for survey 
participation
Pulmonologists from the three Belgian regions (Brussels-
Capital, Flanders, and Wallonia) were identified through 
an available listing as potential participants to the survey 
if they were involved in the treatment of both adult asthma 
and COPD patients. Selected participants were contacted by 
e-mail or phone. Experts who prepared the survey question-
naire were excluded from participating.
survey
The survey was developed by a panel of Belgian experts 
in the field of COPD and asthma from the three Belgian 
regions. The survey included four different questions. 
Predefined criteria to diagnose COPD and asthma patients 
as ACOS patients were identified by the experts based on 
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published guidelines.2 This survey contained only general 
questions to pulmonologists about what they considered to be 
important for the diagnosis of a disease (ACOS); no patients 
were involved and no specific patient data were collected. 
Therefore, the expert panel declared that no involvement 
from an ethical committee was required, and this was con-
firmed by contacting the ethical committee from University 
of Liege (Belgium).
The first question of the survey was an open-ended ques-
tion: “What are the most important criteria that make you 
think of ACOS in a patient? List at least three criteria and 
rank them from most to least important.” The second and 
third questions were close-ended questions, in which the 
survey participants were asked to score predefined criteria 
by their level of importance, concerning the following topics: 
“What features are decisive to qualify a COPD patient as 
ACOS patient?” and “What features are decisive to qualify 
an asthma patient as ACOS patient?” Survey participants 
had no access to these criteria before having finalized their 
answer to question one. As a subquestion for questions two 
and three, the participants were asked to select the three 
most important criteria. The fourth question was again open: 
“What are the most important criteria for you to prescribe 
ICS to a COPD patient? List at least three criteria and rank 
them from most to least important.”
To avoid bias in the scoring of the predefined criteria, 
questionnaires were designed to contain one criterion per 
screen-page, and correction of entries after completion of 
each page was not possible. In addition, two versions of the 
questionnaire were developed with differences in the order 
of questions two and three, in both main national languages 
(French and Dutch). Pulmonologists who accepted to par-
ticipate were randomized to receive either one of the two 
available questionnaires. Duplication of questionnaires was 
avoided by asking each participant to encode his/her name 
and e-mail address.
analysis of the survey answers
Answers to open-ended questions one and four were 
grouped in clusters according to similarity of provided 
answers. For example, for question one, the answers 
“smoking cessation”, “history of smoking”, “nicotine use”, 
or “number of pack-years” were grouped together in the 
cluster “smoking”.
For the close-ended questions two and three, a Likert 
scale22 was used with a score ranging from 1 to 7. Scores were 
defined in the questionnaire as follows: 1= very  irrelevant; 
2= irrelevant; 3= partially irrelevant; 4= I do not know/
not sure/no opinion; 5= partially relevant; 6= relevant; and 
7= very relevant. During the analysis, scores 5–7 were con-
sidered as “relevant” criteria and grouped together.
In addition to the answers on the four abovementioned 
questions, the following background information was col-
lected for each survey participant: the type of hospital the 
pulmonologist is working at (nonacademic/academic), the 
number of years of practice (0–5/5–10/10–20/20 years), 
geographical location (Flanders, Wallonia, Brussels-
Capital), repartition of asthma to COPD patients being 
treated by the pulmonologist (0%–100%, 25%–75%, 
50%–50%, 75%–25%, or 100%–0%), and the sex of the 
pulmonologist.
guidance for the diagnosis of aCOs
Based on the results from the survey, guidance for the 
diagnosis of ACOS was proposed by the expert panel. 
A methodology similar to the Spanish consensus on ACOS3 
was implemented. Criteria that were considered relevant 
(Likert score 5–7) by 70% of the survey participants were 
retained for the development of guidance to consider ACOS 
in COPD or asthma patients.
The two criteria that were rated “relevant” by the highest 
percentage of pulmonologists for each close-ended question 
were chosen as major criteria, and all other criteria that sur-
passed the 70% cutoff for “relevant” criteria were included 
in the recommendations as minor criteria. The expert panel 
agreed that presence of two major criteria and at least one 
minor criterion was required for a reliable diagnosis of ACOS 
both in asthma and COPD patients.
statistics
The results from the survey were analyzed using descrip-
tive statistics (frequencies and percentages for categorical 
variables; mean, standard deviation, median, and first and 
third quartiles for continuous variables). Cross-tabulation 
was used for comparisons between categories. Percent-
ages were calculated according to the number of available 
answers.
Results
survey participants
The survey was conducted between October 21 and 
December 10, 2015. Out of the 372 pulmonologists invited to 
participate in the survey, 87 adequately completed the ques-
tionnaire (response rate of 23.4%) (Figure 1). Characteristics 
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of the participants are shown in Table 1. The participants 
can be considered as a representative sample of the whole 
Belgian population of pulmonologists invited to participate 
(data not shown).
Important criteria for the diagnosis 
of aCOs
As shown in Figure 2, 77% of the pulmonologists mentioned 
“reversibility in lung function and/or airway obstruction” as 
the most important criterion related to the diagnosis of ACOS 
(survey open-ended question one). Other commonly reported 
criteria were “history or diagnosis of asthma”, “allergy or 
atopy”, and “smoking”, which were very often cited in 
association with the most frequently mentioned criterion – 
reversibility – (60%–84% depending on the criterion). All 
reported criteria are summarized in Table S1.
Criteria to qualify a COPD patient 
as aCOs patient
Fifteen criteria were predefined by the group of experts 
and ranked by each participant on a Likert scale (Figure 3, 
Table 2). The two criteria that were considered “relevant” 
(Likert score 5–7) by the highest percentage of pulmonolo-
gists and retained as major criteria were “degree of variability 
of airway obstruction” and “degree of response to broncho-
dilators”. Other criteria that were considered to be relevant 
by more than 70% of the pulmonologists and proposed as 
minor criteria were “personal history of allergy or sensitivity 
to one or more allergens”, “elevated eosinophils in sputum 
or blood or high nitric oxide levels”, ‘diagnosis of asthma 
before the age of 40”, “symptoms variability”, and “age 
(in favor of asthma)”.
Additionally, the participants were asked to select the 
three most important criteria to qualify a COPD patient as 
an ACOS patient. The most important criteria, as chosen 
by 49% of the pulmonologists, were “degree of response 
to bronchodilators” and “degree of variability in airway 
obstruction”; “asthma diagnosis before 40 years of age” 
was selected by 46%; “personal or family history of atopy” 
Figure 1 Participant flow chart.
???
???????????????????????????????
???????????????????????????????????????????
?????????????????????
???????????????????????????????????????????????
???????????????????
??????????????????? ?????????????????????????
??????????????????? ????????????????????????????????????????
???????????????????????????????????????????????????????????????
????????????????????????????????????????????
Table 1 Characteristics of participants (n=87)
Characteristics n (%)
sex
Male 49 (56.3)
Female 38 (43.7)
Years of practice
20 35 (40.2)
10–20 21 (24.1)
5–10 19 (21.8)
5 12 (13.8)
hospital type
nonacademic 66 (75.9)
academic 21 (24.1)
region
Flanders 44 (50.6)
Wallonia 31 (35.6)
Brussels 12 (13.8)
Proportion asthma/COPD treated
50/50 41 (47.1)
25/75 40 (46.0)
75/25 6 (6.9)
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Figure 2 Major criteria for diagnosing aCOs.
Notes: The bubble size and presented number and percentage (in gray) indicate the number and percentage of pulmonologists who considered the criterion relevant for 
the diagnosis of aCOs. Overlap with the main reported criterion shows the number of each combination (indicated in blue) of both answers provided by pulmonologists. 
Overlap between the other criteria is not shown.
Abbreviations: aCOs, asthma–COPD overlap syndrome; FenO, fractional exhaled nitric oxide.
???????????????????????????? ???????????????????????????????????
???????????????????????????
????????????????????????????????????
???????
???????
????????
????
??????????
?? ??
??
?? ??
?????????????????????????????????????????????????????????????????
??
????????????????????????????????????????????????
???????????????????????????
??????????????????????????????????????????? ?????????????????????
??????????????????????
???????????????????????????????????????????
??????????????????????????
?????????????????????????????????????????????
???????????????????????
?????????????
?????????????????????????????????????????????????????????
???????????????????
?????????????????????????????????????????????????????????????????????????????????????
????????
? ? ? ? ? ? ?
? ?? ?? ?? ?? ???
???????????????????????????
????? ??????????????????????????????????????????????????
Figure 3 Features to diagnose a COPD patient as aCOs patient.
Notes: gray bars show the percentage of pulmonologists who considered the criterion as “relevant” (likert score 5–7). The two criteria considered relevant by most 
pulmonologists were retained as major criteria. Other criteria surpassing the 70% cutoff mark for relevancy (vertical dashed line) were considered as minor criteria. Black 
bullet shows mean likert score (with sD).
Abbreviations: aCOs, asthma–COPD overlap syndrome; Ige, immunoglobulin e; FenO, fractional exhaled nitric oxide; CT, computed tomography; n, number of 
pulmonologists; sD, standard deviation.
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by 45%; and “elevated blood or sputum eosinophil levels or 
increased fractional exhaled nitric oxide (FeNO)” by 44% 
of participants (Table S2).
Criteria to qualify an asthma patient as 
aCOs patient
Fifteen criteria predefined by the group of experts were 
ranked by each participant on a Likert-scale (Figure 4, 
Table 2). As done for close-ended question two, the two 
criteria that were considered “relevant” (Likert score 5–7) by 
most pulmonologists were retained as major criteria. These 
were “persistence over time of an obstructive disorder (no 
normalization of FEV
1
/FVC ratio)” and “smoker (former 
or active smoker)”. Other criteria that were considered to 
be relevant by more than 70% of the pulmonologists were 
indicated as minor criteria. These were “degree of response 
to bronchodilators, as measured on pulmonary function tests 
(PFTs)”, “reduced lung diffusion capacity”, “degree of vari-
ability in airway obstruction on PFTs”, “age”, and “presence 
of emphysema on chest CT scan”.
Table 2 Criteria for aCOs diagnosis: guidance from the Belgian survey
ACOS in a COPD patient ACOS in an asthma patient
Major criteria Major criteria
 high degree of variability in airway obstruction over time 
(PFTs): FeV1 variation 400 ml
 Persistence over time of airflow obstruction (persistence of FEV1/FVC 
ratio 0.7 or  lower normal limit)
 high degree of response to bronchodilators (PFTs): 200 ml 
and 12% predicted above baseline
 exposure to noxious particles or gases, with 10 pack-years in case 
of smoking for (ex-)smokers
Minor criteria Minor criteria
 Personal or family history of atopy and/or Ige sensitivity to one 
or more airborne allergens
 lack of response on acute bronchodilator test
 elevated blood or sputum eosinophils or increased FenO  reduced lung diffusion capacity (on PFTs)
 Diagnosed with asthma before the age of 40  little variability in airway obstruction (PFTs)
 symptom variability  age in favor of COPD (ie, 40 years)
 age (in favor of asthma)  Presence of emphysema on chest CT scan
Note: a diagnosis of aCOs is accepted in both COPD and asthma patients when the two major criteria and at least one minor criterion are met.
Abbreviations: aCOs, asthma–COPD overlap syndrome; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PFTs, pulmonary function tests; 
Ige, immunoglobulin e; FenO, fractional exhaled nitric oxide; CT, computed tomography.
??????????????????? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
? ? ? ? ? ? ?
? ?? ?? ?? ?? ???
???????????????????????????
????? ??????????????????????????????????????????????????
Figure 4 Features to diagnose an asthma patient as aCOs patient.
Notes: Figure shows the percentage of pulmonologists who considered the criterion as “relevant” (likert score 5–7). The two criteria considered relevant by most 
pulmonologists were retained as major criteria. Other criteria surpassing the 70% cutoff mark for relevancy (vertical dashed line) were considered as minor criteria. Black 
bullet shows mean likert score (with sD).
Abbreviations: aCOs, asthma–COPD overlap syndrome; CT, computed tomography; FenO, fractional exhaled nitric oxide; Ige, immunoglobulin e; n, number of 
pulmonologists; sD, standard deviation.
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Similar results were obtained when the pulmonologists 
were asked to select the three most important criteria. “Per-
sistence over time of an obstructive disorder” was selected 
by 70% of pulmonologists, “smoking (former or active 
smoker)” by 66%, “presence of emphysema on chest com-
puted tomography (CT) scan” by 45%, and “reduced lung 
diffusion capacity” by 32% (Table S3).
Criteria to prescribe ICs to 
a COPD patient
When the pulmonologists were asked to state the most 
important criteria to prescribe ICS to a COPD patient, 
“exacerbations” was the most frequently mentioned criterion, 
reported by 89% of survey participants. Other commonly 
reported criteria were “eosinophilia/increased FeNO” and 
“reversibility in lung function and/or airway obstruction” 
(Figure 5).
guidance for aCOs diagnosis proposed 
by the expert panel
It was agreed upon by the expert panel that presence of 
two major criteria and at least one minor criterion would 
be required for the diagnosis of ACOS, both in asthma and 
COPD patients. The criteria that were proposed based on the 
findings from the survey are summarized in Table 2. Where 
possible, the findings from the survey were expanded with 
cutoff values.
Discussion
This survey documents the criteria considered as relevant by 
pulmonologists in Belgium to diagnose ACOS in patients 
suffering from asthma or COPD, and accordingly proposes 
a guideline for ACOS diagnosis is.
While patients with characteristics of both asthma and 
COPD have been largely excluded from clinical trials, ACOS 
has increasingly retained interest. In 2014, guidelines for the 
diagnosis of ACOS were proposed in a joint effort of GINA 
and GOLD,2 and the syndrome is also appearing in national 
clinical practice guidelines.23–27
Clearly defined criteria for the diagnosis of ACOS are 
important for several reasons. First, ACOS patients probably 
display specific clinical and functional trajectories with a 
generally more severe disease and worse prognosis than 
asthma or COPD patients without overlap. For example, 
ACOS patients have a higher frequency of exacerbations 
and subsequent hospitalizations, which result in signifi-
cantly higher health care costs compared to patients with 
COPD or asthma alone.28–32 Second, there are also indica-
tions that ACOS patients display a systemic disease with 
inflammation33,34 and may even have an increased risk for 
the development of nonrespiratory cancers.35 Finally, the 
societal burden impacting daily activities is believed to 
be more important in ACOS patients than in patients with 
asthma or COPD alone.36
In the experience of the experts, ACOS will rarely appear 
as a first clinical diagnosis; physicians usually start with the 
most likely diagnosis (asthma or COPD), and may then move 
to a diagnosis of ACOS during follow-up based on the evolu-
tion across time (eg, lung function, variability in symptoms) 
of the patient. Therefore, the two close-ended questions of 
this survey were set up to diagnose ACOS either in a COPD 
or in an asthma patient.
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Figure 5 Major criteria for prescribing ICs to COPD patients.
Note: Figure shows the percentage of pulmonologists who considered the criterion important for prescribing ICs to COPD patients.
Abbreviations: ICs, inhaled corticosteroids; FenO, fractional exhaled nitric oxide; gOlD, global Initiative for Chronic Obstructive lung Disease; aCOs, asthma–COPD 
overlap syndrome; n, number of pulmonologists.
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Criteria to diagnose aCOs in COPD 
or asthma patients
About 80% of participating pulmonologists considered 
“degree of reversibility in lung function and/or airway 
obstruction” as an important criterion related to ACOS 
(regardless of the previous diagnosis of the patient, ie, COPD 
or asthma). Since other answers showed a lower level of con-
sensus among pulmonologists (50% or less similar answers), 
it was difficult to propose a set of clear-cut criteria based on 
the answers provided to open-ended question one. As already 
mentioned, ACOS is rarely diagnosed at the initial assess-
ment, and so it is easier to develop recommendations con-
sidering a patient with a first presumed diagnosis of COPD 
or asthma. Of note, the level of consensus was higher for the 
ranking of predefined criteria for the diagnosis of ACOS in 
a COPD patient compared to an asthma patient.
Based on the answers of pulmonologists to the survey 
and the subsequent discussion by the expert panel, recom-
mendations are proposed to diagnose ACOS in COPD and 
asthma patients (Table 2). In both COPD and asthma, the 
patient should meet the two major criteria and at least one 
minor criterion to be classified as a possible ACOS patient.
The two major criteria to diagnose a COPD patient as 
potential ACOS patient were “high degree of variability in 
airway obstruction over time” and “pronounced response to 
bronchodilators”. The cutoffs proposed by the expert panel 
are an increase of 400 mL over time as degree of variability 
in airway obstruction,2 an increase in FEV
1
 of 200 mL, and 
a 12% increase relative to baseline level for acute response 
to bronchodilators.37
The two major criteria to diagnose an asthma patient as 
ACOS were “persistence over time of an obstructive disorder” 
and “smoker (former/active)”. The panel of experts recom-
mends to include “exposure to noxious particles and gases”, 
also so as to encompass other exposures than smoking, for 
example professional exposures. In addition, for smoking, a 
cutoff of 10 pack-years was defined, which is considered 
to reflect a significant exposure to tobacco smoke.
The other quantifiable minor criteria were not further 
detailed by the expert panel since scientific data are lacking 
to define validated cutoff values. These minor criteria were 
elevated eosinophils or increased FeNO and symptom vari-
ability for COPD patients, and lack of response on acute bron-
chodilator test, reduced lung diffusion capacity, little variability 
in airway obstruction, and presence of emphysema on chest 
CT scan for asthma patients. As there is no consensus in the 
literature, precise cutoff levels for eosinophil counts and FeNO 
levels were not proposed as part of the criteria. However, levels 
of 300 eosinophils/mm3 have been suggested elsewhere;9,38 for 
FeNO levels, suggested cutoff values to classify patients as hav-
ing ACOS range from 19 bbp39 over 22.5 bbp40 to 35 bbp.41
The findings of this survey are in general agreement with 
criteria reported for diagnosis of ACOS in COPD patients in 
the Spanish consensus paper3 and with the criteria for ACOS 
diagnosis proposed by a global expert panel.9 Bronchodila-
tor reversibility, history of asthma, and airway eosinophilia 
are widely accepted criteria to raise suspicion for an asthma 
component in a COPD patient.3,9 Bronchodilator response 
was indicated as a major criterion in this survey as well 
as by the Spanish and global expert panels, although the 
Belgian experts proposed a less stringent cutoff (200 mL 
and 12% above baseline, compared to 400 mL and 15% 
in the other studies3,9). The other two major criteria from 
the Spanish consensus3 (history of asthma before age 40, 
and eosinophilia) were indicated as minor criteria in the 
Belgian proposal. The global expert panel9 also chose his-
tory of asthma before 40 years of age as a major criterion, 
while elevated blood eosinophils was a minor criterion. The 
other two major criteria proposed by the global expert panel9 
(persistent airflow obstruction and air pollution exposure 
or 10 pack-years) corresponded to the major criteria 
proposed by the Belgian expert panel for the diagnosis of 
ACOS in an asthma patient. Surprisingly, one major criterion 
in COPD patients proposed by the Belgian experts – high 
variability in airway obstruction over time – was not men-
tioned in the two other studies. The Belgian experts feel 
this criterion is important as it may comprise an unexpected 
major treatment response over time, which is indicative of 
major reversibility and a preferred asthma feature. Finally, 
the number of major and minor criteria that should be present 
to diagnose a patient with ACOS differs across the studies. 
As there is no gold standard, it is impossible to compare 
which of them is best.
The strengths and novelty of the Belgian expert recom-
mendations are found in the fact that they provide, for the first 
time, specific criteria for previously diagnosed asthma patients 
in whom the suspicion of ACOS is raised during follow-up. 
The importance of diagnosing ACOS in asthma patients has 
been demonstrated in a recent assessment on the long-term 
prognosis of ACOS patients.42 While a poor prognosis was 
observed for all ACOS patients, the prognosis seemed to be 
affected by the age at diagnosis of asthma. Indeed, ACOS 
patients with late-onset asthma (after the age of 40) display 
the worst prognosis, indicating the need for early diagnosis 
and closer follow-up.42 Expert groups in Czech Republic and 
Finland included ACOS in their recently published national 
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guidelines for the diagnosis and treatment of COPD.23,27 These 
two groups built their guidelines based on the GOLD report 
and the Spanish COPD guidelines, which are similar to the 
approach used here for the development of the survey.
Most importantly, evidence-based guidelines for the treat-
ment of ACOS patients do not exist, and without a correct 
diagnosis, patients might not receive the appropriate treat-
ment. To clearly delineate this important group of patients 
for future interventional studies, a consensus on whom to 
consider as an ACOS patient is required. The problem of 
inconsistent definitions used in treatment studies, which 
makes it difficult to determine the most effective therapy 
for a particular patient, has already been brought forward by 
other authors.9,43 The present survey largely supports their 
suggestion of extensive phenotypic characterization of indi-
vidual patients before inclusion in clinical trials. However, 
although Postma and Rabe43 found it currently premature to 
designate ACOS as a disease entity, the Belgian expert panel 
believes that the criteria proposed here and by other groups 
will provide valuable guidance for physicians in the assess-
ment of their patients and will make possible the design of 
specific studies focused on these specific patients.
Criteria considered by Belgian 
respiratory physicians for initiation 
of ICs in COPD patients
In accordance with the GOLD statement and a number of 
previous studies showing that ICS reduce the risk of exac-
erbations in COPD patients with frequent exacerbations,44–46 
about 90% of pulmonologists in this survey considered “exac-
erbations” as a criterion to prescribe ICS to a COPD patient. 
Nevertheless, while triple therapy (LABA/LAMA/ICS) is 
recommended only for COPD patients classified as GOLD D 
(FEV
1
 after bronchodilator 50% predicted and/or a history 
of two or more exacerbations per year; or one or more hos-
pitalizations for a COPD exacerbation as well as a modified 
Medical Research Council [mMRC] grade 2; or a COPD 
assessment test score 10),47 it is very often also prescribed 
to COPD patients classified as GOLD A, B, or C.48 The appro-
priateness of such a triple therapy in non-GOLD D patients 
is questionable. The most common pathway to triple therapy 
was observed to be a prescription of LABA/ICS combination 
before COPD diagnosis, followed by addition of LAMA at 
the time of appropriate COPD diagnosis.48 The experts who 
conceived the present survey recommend reasonable use of 
(low-dose) ICS in patients with frequent bacterial exacerba-
tions in view of the increased risk of community-acquired 
pneumonia and other respiratory infections.
In COPD patients, eosinophilic airway inflammation may 
play a role in exacerbations, especially in more severe cases. 
Sputum eosinophils have been identified as a risk factor for 
COPD exacerbations upon withdrawal of ICS in COPD.49,50 
Thus, increased sputum eosinophil levels appear to be a use-
ful indicator for initiating ICS therapy in order to reduce the 
risk of exacerbations.
In clinical practice, patients with a mixed phenotype often 
receive a combination of asthma and COPD medications; 
however, this is merely based on extrapolation. In the survey 
presented here, at least 22% of the participating pulmonolo-
gists indicated that a diagnosis of ACOS is a major criterion 
for initiating ICS in COPD patients. Other studies are defi-
nitely needed to provide the necessary evidence for validating 
this common practice. Such studies might validate a treatment 
approach based on a LABA/LAMA combination as standard 
treatment for COPD, an ICS/LABA combination as standard 
for asthma, and a triple therapy in case of ACOS.
survey strengths and limitations
About a quarter of the pulmonologists who were invited to 
participate in the survey successfully completed the ques-
tionnaire. This was, to our knowledge, the largest group 
of specialist practitioners who were consulted to develop a 
consensus on the diagnosis of ACOS. Additionally, this paper 
is the first to provide guidance for the diagnosis of ACOS 
in asthma patients.
A limitation of the findings presented here is the fact 
that insufficient information is currently available to provide 
specific cutoffs for the minor criteria identified for the diag-
nosis of ACOS in asthma and COPD patients. The specialist 
practitioners should assess, based on their experience, if the 
specified criterion is met in their COPD or asthma patients.
Conclusion
Our survey points out the criteria considered by Belgian pul-
monologists as relevant to the diagnosis of ACOS, and based 
on this survey, a consensus on ACOS diagnosis in patients 
suffering from asthma or COPD is proposed. Criteria used 
to classify COPD patients as ACOS were largely similar to 
those used to prescribe ICS in COPD patients in Belgium 
(apart from COPD exacerbations, an indication accepted 
for a long time).
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Table S1 Major criteria for diagnosing aCOs
Criteria n (%)
reversibility in lung function and/or airway obstruction 67 (77)
history/diagnosis of asthma 39 (45)
allergy/atopy 38 (44)
smoking 36 (41)
Persistent airway obstruction 22 (25)
eosinophilia/increased FenO 21 (24)
COPD 15 (17)
age 19 (22)
exacerbations 13 (15)
Obstructive lung function 11 (13)
Variability in lung function and/or airway obstruction 9 (10)
response to corticosteroids 8 (9)
airway hyperresponsiveness 7 (8)
lung diffusion 5 (6)
Variability in symptoms 5 (6)
Othersa 38 (44)
Notes: aOthers: bronchospasm (4), cough (1), dyspnea (2), wheezing (2), chronic 
bronchitis (2), chronicity (1), response to therapy (2), clinic (4), lung function (1), 
impairment of bronchioles (1), emphysema (4), efficacy (1), availability (1), 
performance (1), spirometry (3), nocturnal symptoms (1), rhinitis (4), progressive (1), 
COPD in light smokers (1), and quality of life (1).
Abbreviations: aCOs, asthma–COPD overlap syndrome; n (%), number 
(percentage) of pulmonologists (total: 87); FenO, fractional exhaled nitric oxide.
Supplementary materials
Table S2 Most important criteria to diagnose a COPD patient as aCOs patient
Items (n=15) Number of answers (N=261)a % of pulmonologistsa
Degrees of response to bronchodilator testing during spirometry 43 49.43
Degree of variability in airway obstruction, tested by spirometry at different time points 43 49.43
Diagnosed with asthma before the age of 40 years 40 45.98
Personal or family history of atopy/(or, more specifically, IgE sensitivity to one or more  
airborne allergens)
39 44.83
elevated eosinophil levels in blood or sputum, or increased FenO 38 43.68
symptoms variability 20 22.99
Former smoker/active smoker 20 22.99
Wheezing 6 6.90
age 3 3.45
nocturnal symptoms 3 3.45
emphysema on chest CT scan 2 2.30
reduced lung diffusion 2 2.30
Chronic cough 1 1.15
Increased lung volume (hyperinflation) 1 1.15
sputum production 0 0.00
Notes: aThe number and percentage of participants who identified the question two criterion specified as one of the three most important in the diagnosis of ACOS in a 
COPD patient. Dark and light gray underline, respectively, indicate major and minor criteria included in the aCOs diagnosis guidance.
Abbreviations: aCOs, asthma–COPD overlap syndrome; Ige, immunoglobulin e; FenO, fractional exhaled nitric oxide; CT, computed tomography; n, total number of 
answers.
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Table S3 Most important criteria to diagnose an asthma patient as aCOs patient
Items (n=15) Number of answers (N=261)a % of pulmonologistsa
Persistence over time of an obstructive disorder (no normalization) 61 70.11
Former smoker/active smoker 57 65.52
emphysema on chest CT scan 39 44.83
reduced lung diffusion 28 32.18
Degree of response to bronchodilators during spirometry 18 20.69
Degree of variability in airway obstruction, tested by spirometry  
at different time points
16 18.39
age 9 10.34
sputum production 8 9.20
elevated blood or sputum eosinophils or increased FenO 7 8.05
Increased lung volume (hyperinflation) 5 5.75
symptoms variability 4 4.60
Chronic cough 4 4.60
Personal or family history of atopy 3 3.45
nocturnal symptoms 2 2.30
Wheezing 0 0.00
Notes: aThe number and percentage of participants who identified the question three criterion specified as one of the three most important in the diagnosis of ACOS in an 
asthma patient. Dark gray indicates the major criteria included in the aCOs diagnosis guidance, light gray the minor criteria.
Abbreviations: aCOs, asthma–COPD overlap syndrome; CT, computed tomography; FenO, fractional exhaled nitric oxide; n, total number of answers.
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